G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2024 16h20 HE | G1 Therapeutics
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1_Logo_2022_Reg.png
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
28 févr. 2024 06h30 HE | G1 Therapeutics
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
G1_Logo_2022_Reg.png
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
27 févr. 2024 08h30 HE | G1 Therapeutics
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
G1_Logo_2022_Reg.png
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
15 févr. 2024 08h30 HE | G1 Therapeutics
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
G1_Logo_2022_Reg.png
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
12 févr. 2024 16h05 HE | G1 Therapeutics
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
G1_Logo_2022_Reg.png
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 06h45 HE | G1 Therapeutics
G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference.
G1_Logo_2022_Reg.png
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 09h00 HE | G1 Therapeutics
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 janv. 2024 16h51 HE | G1 Therapeutics
January 2024 Inducement Grants
G1_Logo_2022_Reg.png
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
05 déc. 2023 09h26 HE | G1 Therapeutics
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 déc. 2023 16h27 HE | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...